346 related articles for article (PubMed ID: 22461121)
1. Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review.
Talati R; Scholle JM; Phung OP; Baker EL; Baker WL; Ashaye A; Kluger J; Coleman CI; White CM
Pharmacotherapy; 2012 Apr; 32(4):314-22. PubMed ID: 22461121
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
[TBL] [Abstract][Full Text] [Related]
3. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy?
Holtkamp M; Theodore WH
Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004
[TBL] [Abstract][Full Text] [Related]
4. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies.
Yamada M; Welty TE
Ann Pharmacother; 2011 Nov; 45(11):1406-15. PubMed ID: 22028417
[TBL] [Abstract][Full Text] [Related]
5. Side effects of phenobarbital in epilepsy: a systematic review.
Zhang LL; Zeng LN; Li YP
Epileptic Disord; 2011 Dec; 13(4):349-65. PubMed ID: 21926048
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of generic versus brand-name antiepileptic medications.
Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
[TBL] [Abstract][Full Text] [Related]
7. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
[TBL] [Abstract][Full Text] [Related]
8. Vigabatrin versus carbamazepine monotherapy for epilepsy.
Xiao Y; Gan L; Wang J; Luo M; Luo H
Cochrane Database Syst Rev; 2012 Jan; 1():CD008781. PubMed ID: 22258989
[TBL] [Abstract][Full Text] [Related]
9. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
[TBL] [Abstract][Full Text] [Related]
10. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
[TBL] [Abstract][Full Text] [Related]
11. Association between switching antiepileptic drug products and healthcare utilization: A systematic review.
Kwan P; Palmini A
Epilepsy Behav; 2017 Aug; 73():166-172. PubMed ID: 28641169
[TBL] [Abstract][Full Text] [Related]
12. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials.
Temkin NR
Epilepsia; 2001 Apr; 42(4):515-24. PubMed ID: 11440347
[TBL] [Abstract][Full Text] [Related]
13. Recommendations of the Italian League against Epilepsy working group on generic products of antiepileptic drugs.
Perucca E; Albani F; Capovilla G; Bernardina BD; Michelucci R; Zaccara G
Epilepsia; 2006; 47 Suppl 5():16-20. PubMed ID: 17239100
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
Berg M; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Switzer RD; Privitera MD
JAMA Neurol; 2017 Aug; 74(8):919-926. PubMed ID: 28654954
[TBL] [Abstract][Full Text] [Related]
15. Comparing real-life carbamazepine exposure between innovator and generic formulation.
Gaïes E; Jebabli N; Zerei S; Charfi R; Salouage I; Ben Sassi M; El Jebari H; Daghfous R; Trabelsi S
Therapie; 2022; 77(5):523-526. PubMed ID: 35184882
[TBL] [Abstract][Full Text] [Related]
16. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
Das S; Jiang X; Jiang W; Ting TY; Polli JE
Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462
[TBL] [Abstract][Full Text] [Related]
17. Losigamone add-on therapy for partial epilepsy.
Xiao Y; Luo M; Wang J; Luo H
Cochrane Database Syst Rev; 2012 Jun; (6):CD009324. PubMed ID: 22696384
[TBL] [Abstract][Full Text] [Related]
18. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
Tomson T; Battino D; Bonizzoni E; Craig J; Lindhout D; Sabers A; Perucca E; Vajda F;
Lancet Neurol; 2011 Jul; 10(7):609-17. PubMed ID: 21652013
[TBL] [Abstract][Full Text] [Related]
19. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.
Kesselheim AS; Stedman MR; Bubrick EJ; Gagne JJ; Misono AS; Lee JL; Brookhart MA; Avorn J; Shrank WH
Drugs; 2010 Mar; 70(5):605-21. PubMed ID: 20329806
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
